Wang et al., 2024 - Google Patents
Innate immune sensing of lysosomal dysfunction drives multiple lysosomal storage disordersWang et al., 2024
- Document ID
- 18259783577165644439
- Author
- Wang A
- Chen C
- Mei C
- Liu S
- Xiang C
- Fang W
- Zhang F
- Xu Y
- Chen S
- Zhang Q
- Bai X
- Lin A
- Neculai D
- Xia B
- Ye C
- Zou J
- Liang T
- Feng X
- Li X
- Shen C
- Xu P
- Publication year
- Publication venue
- Nature Cell Biology
External Links
Snippet
Lysosomal storage disorders (LSDs), which are characterized by genetic and metabolic lysosomal dysfunctions, constitute over 60 degenerative diseases with considerable health and economic burdens. However, the mechanisms driving the progressive death of …
- 208000015439 Lysosomal storage disease 0 title abstract description 61
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | Microglial MERTK eliminates phosphatidylserine‐displaying inhibitory post‐synapses | |
| Niere et al. | Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression | |
| Ai et al. | MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats | |
| Chen et al. | Functional characterization of Klippel–Trenaunay syndrome gene AGGF1 identifies a novel angiogenic signaling pathway for specification of vein differentiation and angiogenesis during embryogenesis | |
| Wang et al. | Innate immune sensing of lysosomal dysfunction drives multiple lysosomal storage disorders | |
| US20220040333A1 (en) | Use of neuroglobin agonist for preventing or treating mitochondrial RCCI and/or RCCIII deficiency disease | |
| Schuchman | Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy | |
| US9725719B2 (en) | Compositions and methods for inhibiting NF-κB and SOD-1 to treat amyotrophic lateral sclerosis | |
| Green et al. | Peripheral gene therapeutic rescue of an olfactory ciliopathy restores sensory input, axonal pathfinding, and odor-guided behavior | |
| Florio et al. | Sustained expression of negative regulators of myelination protects Schwann cells from dysmyelination in a Charcot–Marie–Tooth 1B mouse model | |
| US20220025461A1 (en) | Methods of detecting, preventing, reversing, and treating neurological diseases | |
| CA3190864A1 (en) | Gene therapies for neurodegenerative disorders | |
| WO2008157747A1 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| Ren et al. | KCNH2-3.1 mediates aberrant complement activation and impaired hippocampal-medial prefrontal circuitry associated with working memory deficits | |
| Shan et al. | Distinct requirements for extracellular and intracellular MMP12 in the development of the adult V-SVZ neural stem cell niche | |
| Zhao et al. | MiR‐505 promotes M2 polarization in choroidal neovascularization model mice by targeting transmembrane protein 229B | |
| Pauzuolyte et al. | Systemic gene therapy rescues retinal dysfunction and hearing loss in a model of Norrie disease | |
| Veneri et al. | A novel mouse model of CMT1B identifies hyperglycosylation as a new pathogenetic mechanism | |
| US20140056929A1 (en) | IMMUNOMODULATION BY CONTROLLING INTERFERON-GAMMA LEVELS WITH THE LONG NON-CODING RNA NeST | |
| Qiu et al. | Induction of A Disintegrin and Metalloproteinase with Thrombospondin motifs 1 by a rare variant or cognitive activities reduces hippocampal amyloid-β and consequent Alzheimer’s disease risk | |
| Liu et al. | YIPF5 (p. W218R) mutation induced primary microcephaly in rabbits | |
| De Lorenzo et al. | CDNF rescues motor neurons in three animal models of ALS by targeting ER stress | |
| Davenport et al. | Loss of maspardin attenuates the growth and maturation of mouse cortical neurons | |
| US20220265862A1 (en) | Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for identifying efficacious agents for treatment of the same | |
| US20220041669A1 (en) | Methods of treating or preventing conditions of dendritic and neural spine defects |